CAMBRIDGE, Mass., Oct. 15, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) today announced that it will present preclinical research on two novel potential cancer therapies, MM-398 and MM-141, and an innovative platform for biomarker analysis at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference will take place on October 19-23, 2013 at the Hynes Convention Center in Boston, Massachusetts. Presentations will include preclinical studies of MM-398, a nanolipsomal encapsulated form of irinotecan, and MM-141, a bispecific antibody co-targeting IGF-1R and ErbB3, and their activity in tumor models. Data will be shared in three poster sessions.
Poster Sessions
- Session Title: Novel Assay Technology 1
A205: Development and application of a platform for analysis of protein biomarkers in clinical biopsies of limited quantity
Sunday, October 20, 2013, 12:30 PM – 7:30 PM
Exhibit Hall C-D
- Session Title: Tumor Microenvironment
AC293: Irinotecan sucrosofate liposome injection, MM-398, demonstrates superior activity and control of hypoxia as measured through longitudinal imaging using [18F]FAZA PET compared to free irinotecan in a colon adenocarcinoma xenograft model
Tuesday, October 22, 2013, 12:30 PM – 7:30 PM
Exhibit Hall C-D
- Session Title: Monoclonal Antibodies
C169: MM-141, a bispecific antibody inhibitor of PI3K/AKT/mTOR, attenuates tumor growth and potentiates everolimus in mouse models of anti-hormone therapy-resistant ER/PR+ breast cancer
Tuesday, October 22, 2013, 12:30 PM – 7:30 PM
Exhibit Hall C-D
About Merrimack
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research throughout the research and development process. Merrimack currently has six oncology therapeutics in clinical development. For more information, please visit Merrimack's website at www.merrimackpharma.com .
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.
Media Contacts: Debbie Tseng, Merrimack 617-441-7659 Heather Gitlitz, Spectrum 202-955-6222
